Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Viatris Inc. (VTRS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.65, with a market capitalisation of $19.14B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.43 to $18.39. This page covers its latest market performance, valuation, price trends and company information.
$19.14B | |
$16.54 | |
$18.86 | |
$6.85 | |
$16.65 | |
266.00 | |
9.53M | |
-- | |
$18.39 | |
$9.43 | |
1.46% | |
-- |
Viatris Inc. (VTRS) is trading at $16.65 in pre-market trading as of 2026-09-16 09:19:00, down 0.02% ($0.00) from the previous close of $16.65
Pre-market trading shows how investors are pricing VTRS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Viatris Inc. (VTRS) moved from $16.88 to $16.65, representing a decline of 1.38% ($0.23).
The stock traded between $16.15 and $17.02 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 7.39 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.6%
VTRS is currently trading at $16.65, placing it 80.6% of the way from its 52-week low of $9.43 to its 52-week high of $18.39. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 30000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Viatris Inc. (VTRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.